-
1Academic Journal
Authors: O. V. Azovtseva, T. N. Tkachenko, V. E. Nogovitsina, О. В. Азовцева, Т. Н. Ткаченко, В. Е. Ноговицина
Source: HIV Infection and Immunosuppressive Disorders; Том 17, № 1 (2025); 28-34 ; ВИЧ-инфекция и иммуносупрессии; Том 17, № 1 (2025); 28-34 ; 2077-9828 ; 10.22328/2077-9828-2025-17-1
Subject Terms: устойчивый вирусологический ответ, HIV infection, therapy, sustained virological response, ВИЧ-инфекция, терапия
File Description: application/pdf
Relation: https://hiv.bmoc-spb.ru/jour/article/view/981/624; Gill K., Ghazinian H., Manch R. et al. Hepatitis C virus as a systemic disease: reaching beyond the liver // Hepatol. Int. 2016. Vol. 10, No. 3. Р. 415–423. doi:10.1007/s12072-015-9684-3; PMID: 26660706; PMCID: PMC4819925.; Nevola R., Acierno C., Pafundi P.C. et al. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management // Minerva Med. 2021. Vol. 112, No. 2. Р. 188–200. doi:10.23736/S0026-4806.20.07129-3; PMID: 33205641.; Okutan O., Ayten O. Hepatitis C and pulmonary fibrosis // Tuber. Toraks. 2017. Vol. 65, No. 2. Р. 131–137. doi:10.5578/tt.35288; PMID: 28990892.; Hoofnagle J.H. Course and outcome of hepatitis C // Hepatology. 2002. Vol. 36, No. 1. Р. 21–29.; Di Bisceglie A.M. Natural history of hepatitis C: its impact on clinical management // Hepatology. 2000. Vol. 31. Р. 1014–1018.; WHO. Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.; Шаханина И.Л., Осипова Л.А. Экономические потери от инфекционной заболеваемости в России: величины и тенденции // Эпидемиология и инфекционные болезни. 2005. № 4. С. 19–21.; О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2023. 368 с.; Viral Hepatitis Prevention Board. 2011. Available at: http://www.vhpb.org/files/html/Meetings_and_publications/Viral_Hepatitis_New-sletters/vhv19n1.pdf.; Пименов Н.Н., Вдовин А.В., Комарова С.В., Мамонова Н.А., Чуланов В.П., Покровский В.И. Актуальность и перспективы внедрения в России Единого федерального регистра больных вирусными гепатитами В и С // Терапевтический архив. 2013. Т. 85, № 11. С. 4–9.; Результаты мониторинга закупок препаратов для лечения гепатита С в России в 2022 году. Россия, июль 2023 года. https://zdravresource.ru/wp-content/uploads/2023/08/analiz_zakupok_preparatov_dlya_lecheniya_vgs_v_rossijskoj_federaczii.pdf; Management of Hepatitis C and HIV Coinfection. WHO, 2006. 272 p.; Беляков Н.А., Боева Е.В., Загдын З.М., Эсауленко Е.В., Лиознов Д.А., Симакина О.Е. Эпидемиология и течение инфекционных заболева- ний на фоне пандемии COVID Сообщение 1. ВИЧ-инфекция, хронический гепатит С и туберкулез // Инфекция и иммунитет. 2022. Т. 12, № 4. C. 639–650. doi:10.15789/2220-7619-EAC-1958.; Costa-Rocha I.A.D., Silva L.D., Fonseca L. et al. Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with directacting antiviral therapy // Antiviral Res. 2021. Vol. 190. Р. 105073. doi:10.1016/j.antiviral.2021.105073; PMID: 33887350.; Priora M., Realmuto C., Parisi S. et al. Rheumatologic manifestations of hepatitis C in the era of direct-acting antiviral agents // Minerva Gastroenterol. Dietol. 2020. Vol. 66, No. 3. Р. 280–289. doi:10.23736/S1121-421X.20.02680-X; PMID: 32218427.; Ющук Н.Д., Зайратьянц О.В., Знойко О.О., Хрипун А.И., Дудина К.Р., Гудкова С.Б., Климова Е.А., Красненкова С.Ф., Журавлева А.В., Орехов О.О., Белый П.А. Бремя смертности от вирусных гепатитов В и С: методология оценки и показатели в Москве в 2015–2017 гг. // Инфекционные болезни: новости, мнения, обучение. 2018. Т. 7, № 4. С. 8–14. doi:10.24411/2305-3496-2018-14001.; Lo Re V. 3rd, Kallan M.J., Tate J.P., Localio A.R., Lim J.K., Goetz M.B., Klein M.B., Rimland D., Rodriguez-Barradas M.C., Butt A.A., Gibert C.L., Brown S.T., Park L., Dubrow R., Reddy K.R., Kostman J.R., Strom B.L., Justice A.C. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study // Ann. Intern. Med. 2014. Mar 18. Vol. 160, No. 6. Р. 369–379. doi:10.7326/M13-1829.; Lauer G.M., Walker B.D. Hepatitis C virus infection // N. Engl. J. Med. 2001. Vol. 345. Р. 41–52.; Massard J., Ratziu V., Thabut D. et al. Natural history and predictors of disease severity in chronic hepatitis C // J. Hepatol. 2006. Vol. 44 (1 Suppl.). Р. 19–S24.; Рассохин В.В., Боева Е.В. Вопросы эпидемиологии и патогенеза сочетанной инфекции ВГС и ВИЧ // ВИЧ-инфекция и иммуносупрессии. 2020. Т. 12, № 1. С. 32–46 doi: http://dx.doi.org/10.22328/2077-9828-2020-12-1-32-46].; Balagopal A., Philp F.H., Astemborski J. et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C // Gastroenterology. 2008. Vol. 135. Р. 226–233.; Эсауленко Е.В., Сухорук А.А., Понятишина М.В., Ганченко Р.А. Хронический вирусный гепатит С в Северо-Западном федеральном округе // ВИЧ-инфекция и иммуносупрессии. 2017. Т. 9, № 2. С. 74–81. doi:10.22328/2077-9828-2017-9-2-74-81.; Razavi H. et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. European Union HCV Collaborators // Lancet Gastroenterol. Hepatol. 2017. Vol. 2, No. 5. Р. 325–336. doi:10.1016/S2468-1253(17)30045-6.
-
2Academic Journal
Authors: D. E. Danilau
Source: Гепатология и гастроэнтерология, Vol 4, Iss 2, Pp 184-188 (2021)
Subject Terms: гепатит с, гемофилия, лекарственные средства прямого противовирусного действия, устойчивый вирусологический ответ, нежелательные явления, Diseases of the digestive system. Gastroenterology, RC799-869
Relation: http://hepatogastro.grsmu.by/index.php/journalHandG/article/view/164; https://doaj.org/toc/2616-5546; https://doaj.org/toc/2708-5309; https://doaj.org/article/0322a1911fef424882b7a054155de136
-
3Academic Journal
Source: Bulletin of Scientific Research; No. 2 (2019); 13-18 ; Вестник научных исследований; № 2 (2019); 13-18 ; Вісник наукових досліджень; № 2 (2019); 13-18 ; 2415-8798 ; 1681-276X ; 10.11603/2415-8798.2019.2
Subject Terms: occult HCV - infection, liver tissue, peripheral blood mononuclear cells, antiviral treatment, sustained virological response, polymerase chain reaction, оккультная HCV – инфекция, ткань печени, мононуклеары периферической крови, противовирусная терапия, устойчивый вирусологический ответ, полимеразная цепная реакция, окультна HCV – інфекція, тканина печінки, мононуклеари периферичної крові, противірусна терапія, стійка вірусологічна відповідь, полімеразна ланцюгова реакція
File Description: application/pdf
Relation: https://ojs.tdmu.edu.ua/index.php/visnyk-nauk-dos/article/view/10140/9852; https://repository.tdmu.edu.ua//handle/123456789/12812
-
4Academic Journal
Authors: D. V. Umrik, O. M. Tsiroulnikova, I. A. Miloserdov, R. A. Latypov, E. T. Egorova, Д. В. Умрик, О. М. Цирульникова, И. А. Милосердов, Р. А. Латыпов, Е. Т. Егорова
Source: Russian Journal of Transplantology and Artificial Organs; Том 20, № 4 (2018); 54-60 ; Вестник трансплантологии и искусственных органов; Том 20, № 4 (2018); 54-60 ; 1995-1191 ; 10.15825/1995-1191-2018-4
Subject Terms: устойчивый вирусологический ответ, relapse, liver transplantation, direct antiviral action, resistant virologic response, рецидив, трансплантация печени, препараты прямого противовирусного действия
File Description: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/950/754; Klempnauer J, Castaing D, Neuhaus P et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688.; Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010; 10: 1003–1019.; Roche B, Sebagh M, Canfora ML, Antonini T, RoqueAfonso A, Delvart V et al. Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008; 14: 1766–1777. doi:10.1002/lt.21635.; Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int. 2016 Sep; 10 (5): 749–761.; Picciotto FP, Tritto G, Lanza AG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46: 459–465.; Watt K. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009; 9: 1707–1713.; Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32: 673– 684.; Firpi RJ, Clark V, SoldevilaPico C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplantation. 2009; 15: 1063–1071.; European Liver Transplant Registry [Internet]. http://www.eltr.org/ Patient Survival vs Primary Indication. Available from: http://www.eltr.org/Overall-indication-and-results.html.; Zimmermann T, Bocher WO, Biesterfeld S et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007; 20: 583–590.; Jain A, Sharma R, Ryan C et al. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transpl. 2010; 24: 104–111.; Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383.; Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006; 6 (7): 1586–1599.; Raedler LA. Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. American Health & Drug Benefits. 2015; 8: 142–147.; Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), copackaged [prescribing information]. North Chicago, IL: AbbVie Inc; February 2015.; Kwo PY, Mantry PS, Coakley E et al. An interferonfree antiviral regimen for HCV after liver transplantation. The New England Journal of Medicine. 2014; 371: 2375–2382.; Yu ML, Chen YL, Huang CF et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. Journal of the Formosan Medical Association. 2018; 117: 518–526.; Tronina O, Durlik M, Wawrzynowicz-Syczewska M et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/ PTV/r/+DSV±RBV). Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Annals of Transplantation. 2017; 22: 199–207.; https://journal.transpl.ru/vtio/article/view/950
-
5Academic Journal
Authors: О. M. Tsiroulnikova, D. V. Umrik, I. A. Miloserdov, Е. Т. Egorova, R. A. Latypov, О. М. Цирульникова, Д. В. Умрик, И. А. Милосердов, Е. Т. Егорова, Р. А. Латыпов
Source: Russian Journal of Transplantology and Artificial Organs; Том 20, № 4 (2018); 61-68 ; Вестник трансплантологии и искусственных органов; Том 20, № 4 (2018); 61-68 ; 1995-1191 ; 10.15825/1995-1191-2018-4
Subject Terms: устойчивый вирусологический ответ, relapse, liver transplantation, direct antiviral action, 3Dtherapy, sustained virologic response, рецидив, трансплантация печени, препараты прямого противовирусного действия, 3Dтерапия
File Description: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/951/755; Klempnauer J, Castaing D, Neuhaus P et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688.; Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010; 10: 1003–1019.; Firpi RJ, Clark V, SoldevilaPico C, Morelli G, Cabrera R, Levy C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009; 15: 1063–1071.; Forman LM, Lewis JD, Berlin JA et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterol. 2002; 122: 889–96.; Selzner N, Renner E, Selzner M et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009; 88: 1214–1221.; Veldt BJ, Poterucha JJ, Watt KD et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008; 8: 2426–2433.; Carrión JA, Navasa M, GarcíaRetortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterol. 2007; 132: 1746–1756.; Kwo PY, Mantry PS, Coakley E et al. An interferonfree antiviral regimen for HCV after liver transplantation. The New England Journal of Medicine. 2014; 371: 2375–2382.; Yu ML, Chen YL, Huang CF et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. Journal of the Formosan Medical Association. 2018; 117: 518–526.; Tronina O, Durlik M, WawrzynowiczSyczewska M, Buivydiene A, Katzarov K, Kupcinskas L et. al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV). Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBERCEE Study. Ann Transplant. 2017; 22:199–207. doi:10.12659/AOT.903535.; Yu ML, Liu CH, Huang CF et al. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PlOS One. 2012; 7: 520.; Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383.; Zimmermann T, Bocher WO, Biesterfeld S et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007; 20: 583–590.; Wang CS, Ko HH, Yoshida EM et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006; 6: 1586–1599.; Jain A, Sharma R, Ryan C et al. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transpl. 2010; 24: 104–111.; Gonzalez SA. Management of recurrent hepatitis C following liver transplantation. Gastroenterol & Hepatol. 2010; 6: 637–645.; Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008; 14: 58–66.; Aragwal K, Castells L, Müllhaupt B et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. J of Hepatol. 2017; 6: 34–46.; Poordad F, Schiff ER, Vierling JM et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatol. 2016; 63: 1493–1505.; Бакулин ИГ, Сандлер ЮГ, Шарабанов АС. Гематологические нежелательные явления при проведении противовирусной терапии у больных хроническим гепатитом С. Гепатологический форум. 2011; 4: 2–14. Bakulin IG, Sandler JuG, Sharabanov AS. Gematologicheskie nezhelatel’nye javlenija pri provedenii protivovirusnoj terapii u bol’nyh hronicheskim gepatitom S. Gepatologicheskij forum. 2011; 4: 2–14.; Моисеев СВ, Абдурахманов ДТ. Применение кроветворных факторов роста для улучшения результатов противовирусной терапии у пациентов с хроническим гепатитом С. Клиническая гепатология. 2011; 7 (2): 39–43. Moiseev SV, Abdurahmanov DT. Primenenie krovetvornyh faktorov rosta dlja uluchshenija rezul’tatov protivovirusnoj terapii u pacientov s hronicheskim gepatitom S. Klinicheskaja gepatologija. 2011: 7 (2): 39–43.; Afdhal N, Dieterich D, Pockros P et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004; 126: 1302–1311.; Sulkowski М, Wаssеrman R, Brooks L. Changes in haemoglobin during interferon аlрhа-2b plus ribavirin combination therapy for chronic hepatitis С virus infection. J Viral Hepatol. 2004; 11: 243–250.; Toyoda H, Kumada T. Pharmacotherapy of chronic hepatitis C virus infection – the IDEAL trial: ‘2b or not 2b (=2a), that is the question’. Expert Opinion on Pharmacotherapy. 2009; 17: 2845–2857.; Coilly A, FougerouLeurent C, de Ledinghen V et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – the ANRS CUPILT study. J of Hepatol. 2016; 65: 711–718.; Pockros PJ, Reddy KR, Mantry PS et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016; 150: 1590–1598.; https://journal.transpl.ru/vtio/article/view/951
-
6Academic Journal
Authors: N. A. Malinina, N. V. Mazurchik, O. I. Tarasova, P. P. Ogurtsov, Н. А. Малинина, Н. В. Мазурчик, О. И. Тарасова, П. П. Огурцов
Source: Siberian journal of oncology; Том 18, № 3 (2019); 90-96 ; Сибирский онкологический журнал; Том 18, № 3 (2019); 90-96 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2019-18-3
Subject Terms: устойчивый вирусологический ответ, chronic hepatitis C, direct-acting antiviral (DAA) drugs, liver cirrhosis, interferons, sustained virological response, хронический гепатит С, препараты прямого противовирусного действия, цирроз печени, интерфероны
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/1101/642; World Health Organization. Hepatitis C [Internet]. URL: http https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (cited 12.10.2018г.).; О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2017 году: Государственный доклад. М., 2018. 268.; European Association for Study of Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2014 Feb; 60(2): 392–420. doi:10.1016/j.jhep.2013.11.003.; Lafaro K.J., Demirjian A.N., Pawlik T.M. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015 Jan; 24(1): 1–17. doi:10.1016/j.soc.2014.09.001.; Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136(5): E359–86. doi:10.1002/ijc.29210.; Li D., Chung R. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015 Sep 1; 121(17): 2874–82. doi:10.1002/cncr.29528.; Bruno S., Zuin M., Crosignani A., Rossi S., Zadra F., Roffi L., Borzio M., Redaelli A., Chiesa A., Silini E.M., Almasio P.L., Maisonneuve P. Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study. Am J Gastroenterol. 2009 May; 104(5): 1147–58. doi:10.1038/ajg.2009.31.; London W.T., Petrick J.L., McGlynn K.A. Liver cancer. Cancer Epidemiology and Prevention. 4th ed. New York: Oxford University Press, 2018. 635–660.; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi:10.3322/caac.21492.; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М., 2018. 250.; Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году (заболеваемость и смертность). М., 2009. 245.; European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol. 2011 Aug; 55(2): 245–64. doi:10.1016/j.jhep.2011.02.023.; Niederau C., Hüppe D., Zehnter E., Möller B., Heyne R., Christensen S., Pfaff R., Theilmeier A., Alshuth U., Mauss S. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World J Gastroenterol. 2012 Mar 28; 18(12): 1339–47. doi:10.3748/wjg.v18.i12.1339.; Hiramatsu N., Oze T., Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015 Jan; 45(2): 152–61. doi:10.1111/hepr.12393.; Yu M.L., Lin S.M., Chuang W.L., Dai C.Y., Wang J.H., Lu S.N., Sheen I.S., Chang W.Y., Lee C.M., Liaw Y.F. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multicentre study in Taiwan. Antivir Ther. 2006; 11(8): 985–94.; Singal A.K., Singh A., Jaganmohan S., Guturu P., Mummadi R., Kuo Y.F., Sood G.K. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virusrelated cirrhosis. Clin Gastroenterol Hepatol. 2010 Feb; 8(2): 192–9. doi:10.1016/j.cgh.2009.10.026.; Rutter K., Stättermayer A.F., Beinhardt S., Scherzer T.M., SteindlMunda P., Trauner M., Ferenci P., Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015 Mar; 41(6): 521–31. doi:10.1111/apt.13085.; Janjua N.Z., Chong M., Kuo M., Woods R., Wong J., Yoshida E.M., Sherman M., Butt Z.A., Samji H., Cook D., Yu A., Alvarez M., Tyndall M., Krajden M. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017 Mar; 66(3): 504–513. doi:10.1016/j.jhep.2016.10.028.; Morgan T.R., Ghany M.G., Kim H.Y., Snow K.K., Shiffman M.L., De Santo J.L., Lee W.M., Di Bisceglie A.M., Bonkovsky H.L., Dienstag J.L., Morishima C., Lindsay K.L., Lok A.S.; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep; 52(3): 833–44. doi:10.1002/hep.23744.; van der Meer A.J., Veldt B.J., Feld J.J., Wedemeyer H., Dufour J.F., Lammert F., Duarte-Rojo A., Heathcote E.J., Manns M.P., Kuske L., Zeuzem S., Hofmann W.P., de Knegt R.J., Hansen B.E., Janssen H.L. Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA. 2012 Dec 26; 308(24): 2584–93. doi:10.1001/jama.2012.144878.; Yoshida H., Tateishi R., Arakawa Y., Sata M., Fujiyama S., Nishiguchi S., Ishibashi H., Yamada G., Yokosuka O., Shiratori Y., Omata M. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425–430.; Morgan R.L., Baack B., Smith B.D., Yartel A., Pitasi M., FalckYtter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013 Mar 5; 158(5 Pt 1): 329–37. doi:10.7326/0003-4819158-5-201303050-00005.; Bartenschlager R., Lohmann V., Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013 Jul; 11(7): 482–96. doi:10.1038/nrmicro3046.; Kim W.R., Lake J.R., Smith J.M., Skeans M.A., Schladt D.P., Edwards E.B., Harper A.M., Wainright J.L., Snyder J.J., Israni A.K., Kasiske B.L. OPTN/SRTR 2013 Annual Data Report: liver. Am J Transplant. 2015 Jan; 15 Suppl 2: 1–28. doi:10.1111/ajt.13197.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018 Aug; 69(2): 461–511. doi:10.1016/j.jhep.2018.03.026.; Reig M., Mariño Z., Perelló C., Iñarrairaegui M., Ribeiro A., Lens S., Díaz A., Vilana R., Darnell A., Varela M., Sangro B., Calleja J.L., Forns X., Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016 Oct; 65(4): 719–726. doi:10.1016/j.jhep.2016.04.008.; Conti F., Buonfiglioli F., Scuteri A., Crespi C., Bolondi L., Caraceni P., Foschi F.G., Lenzi M., Mazzella G., Verucchi G., Andreone P., Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCVrelated cirrhosis treated with direct-acting antivirals. J Hepatol. 2016 Oct; 65(4): 727–733. doi:10.1016/j.jhep.2016.06.015.; Waziry R., Hajarizadeh B., Grebely J., Amin J., Law M., Danta M., George J., Dore G. Hepatocellular carcinoma risk following directacting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017 Dec; 67(6): 1204–1212. doi:10.1016/j.jhep.2017.07.025.; Kanwal F., Kramer J., Asch S.M., Chayanupatkul M., Cao Y., El-Serag H.B. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 Oct; 153(4): 996–1005.e1. doi:10.1053/j.gastro.2017.06.012.; Innes H., Barclay S.T., Hayes P.C., Fraser A., Dillon J.F., Stanley A., Bathgate A., McDonald S.A., Goldberg D., Valerio H., Fox R., Kennedy N., Bramley P., Hutchinson S.J. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. J Hepatol. 2018 Apr; 68(4): 646–654. doi:10.1016/j.jhep.2017.10.033.; Singer A.W., Reddy K.R., Telep L.E., Osinusi A.O., Brainard D.M., Buti M., Chokkalingam A.P. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018 May; 47(9): 1278–1287. doi:10.1111/apt.14593.; ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016 Oct; 65(4): 734–740. doi:10.1016/j.jhep.2016.05.045.; Cabibbo G., Petta S., Calvaruso V., Cacciola I., Cannavò M.R., Madonia S., Distefano M., Larocca L., Prestileo T., Tinè F., Bertino G., Giannitrapani L., Benanti F., Licata A., Scalisi I., Mazzola G., Cartabellotta F., Alessi N., Barbàra M., Russello M., Scifo G., Squadrito G., Raimondo G., Craxì A., Di Marco V., Cammà C.; Rete Sicilia Selezione Terapia HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017 Oct; 46(7): 688–695. doi:10.1111/apt.14256.; Calvaruso V., Petta S., Cacciola I., Cabibbo G. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. Digestive and Liver Disease. 2018; 50(1): 12. doi:10.1016/j.dld.2018.01.005.; Belli L.S., Perricone G., Adam R., Cortesi P.A., Strazzabosco M., Facchetti R., Karam V., Salizzoni M., Andujar R.L., Fondevila C., De Simone P., Morelli C., Fabregat-Prous J., Samuel D., Agarwaal K., Moreno Gonzales E., Charco R., Zieniewicz K., De Carlis L., Duvoux C.; all the contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAA in liver transplantation: major effects on the evolution of the indications and results. A study based on ELTR registry. J Hepatol. 2018 Oct; 69(4): 810–817. doi:10.1016/j.jhep.2018.06.010.; https://www.siboncoj.ru/jour/article/view/1101
-
7Academic Journal
Authors: Anastasiy, I.A
Source: ACTUAL INFECTOLOGY; № 2.07 (2015); 13-17
Актуальная инфектология-Aktualʹnaâ Infektologiâ; № 2.07 (2015); 13-17
Актуальна інфектологія-Aktualʹnaâ Infektologiâ; № 2.07 (2015); 13-17Subject Terms: гепатит С, стійка вірусологічна відповідь, ГеноФіброТест, hepatitis C, sustained virological response, GenoFibroTest, устойчивый вирусологический ответ, ГеноФиброТест, 3. Good health
File Description: application/pdf
Access URL: http://ai.zaslavsky.com.ua/article/view/78611
-
8Academic Journal
Authors: O. M. Tsiroulnikova, D. V. Umrik, О. М. Цирульникова, Д. В. Умрик
Source: Russian Journal of Transplantology and Artificial Organs; Том 20, № 3 (2018); 105-115 ; Вестник трансплантологии и искусственных органов; Том 20, № 3 (2018); 105-115 ; 1995-1191 ; 10.15825/1995-1191-2018-3
Subject Terms: устойчивый вирусологический ответ, relapse, liver transplantation, direct antiviral action, resistant virologic response, рецидив, трансплантация печени, препараты прямого противовирусного действия
File Description: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/919/738; Всемирная организация здравоохранения [Internet]. Информационный бюллетень. Гепатит С; 2 октября 2017 г. Vsemirnaya organizaciya zdravoohraneniya [Internet]. Informacionnyj byulleten’. Gepatit C; 2 oktyabrya 2017 g. http://www.who.int/ru/news-room/factsheets/detail/hepatitis-c.; Bunchorntavakul C, Reddy KR. Management of hepatitis C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J. Clin. Transl. Hepatol. 2014; 2: 124–133.; Hedskog C, Bhardwaj N, Chang S, Parhy B, Martin R, Zeuzem S et al. Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir-Based Regimens. Reported by Jules Levin. AASLD: The Liver Meeting® 2017, October 20–24, 2017, Washington, DC.; Simmonds P, Becher P, Collett M et al. Family Flaviviridae In: Virus Taxonomy: Ninth report of the International Committee on taxonomy of viruses. Elsevier Science. 2011: 1003–1020.; Орлов СТ, Неверов АД, Михайловская ГВ. Разработка и апробация тест-системы «АмплиСенс HCV-генотип FRT» на клиническом материале и контрольных панелях QCMD. Сборник трудов 6-й Всероссийской НПК с международным участием «Молекулярная диагностика-2007». 2007; 1: 320–323. Orlov ST, Neverov AD, Mihajlovskaya GV. Razrabotka i aprobaciya test-sistemy «AmpliSens HCV-genotip FRT» na klinicheskom materiale i kontrol’nyh panelyah QCMD. Sbornik trudov 6-j Vserossijskoj NPK s mezhdunarodnym uchastiem «Molekulyarnaya diagnostika-2007». 2007; 1: 320–323.; Klempnauer J, Castaing D, Neuhaus P et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J. Hepatol. 2012; 57: 675–688.; Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am. J. Transplant. 2010; 10: 1003–1019.; Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002; 35: 680–687.; Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol. Int. 2016 Sep; 10 (5): 749–761.; Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect. Dis. 2016 Jun; 16 (6): 735–745.; Франк ГА, Ивашкин ВТ, Лукина ЕА и др. Вирус гепатита С в клетках крови и костного мозга у больных с неясными гематологическими синдромами. Гематология и трансфузиология. 2000; 5: 13–17. Frank GA, Ivashkin VT, Lukina EA i dr. Virus gepatita C v kletkah krovi i kostnogo mozga u bol’nyh s neyasnymi gematologicheskimi sindromami. Gematologiya i transfuziologiya. 2000; 5: 13–17.; Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem. World Journal of Gastroenterology : WJG. 2014; 20 (32): 11095–11115. DOI:10.3748/wjg.v20.i32.11095.; Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008; 14 (Suppl 2): 36–44. DOI:10.1002/lt.21646.; Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol. 2000; 32: 673–684.; Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009; 15: 1063–1071.; Hori T, Onishi Y, Kamei H et al. Fibrosing Cholestatic Hepatitis in a Complicated Case of an Adult Recipient After Liver Transplantation: Diagnostic Findings and Therapeutic Dilemma. The American Journal of Case Reports. 2016; 17: 597–604. DOI:10.12659/AJCR.898427.; European Liver Transplant Registry [Internet]. http://www.eltr.org/ Patient Survival vs Primary Indication. Available from: http://www.eltr.org/Overall-indicationand-results.html.; Song ATW, Sobesky R, Vinaixa C et al. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World Journal of Gastroenterology. 2016; 22 (18): 4547–4558. DOI:10.3748/wjg.v22.i18.4547.; Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl. 2003; 9: 897–904/.; Roayaie S, Schiano TD, Thung SN, Emre SH, Fishbein TM, Miller CM et al. Results of retransplantation for recurrent hepatitis C. Hepatology. 2003; 38: 1428–1436.; Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl. 2005; 11: 434–440.; Selzner N, Renner E, Selzner M et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009; 88: 1214–1221.; Veldt BJ, Poterucha JJ, Watt KD et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am. J. Transplant. 2008; 8: 2426–2433.; Carrión JA, Navasa M, García-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132: 1746–1756.; Belli LS et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal of Hepatology. 2016; 65 (3): 524– 553.; Guidelines. EASL Recommendations on Treatment of Hepatitis C 2016. European Association for the Studyof the Liver. Journal of Hepatology. 2017; 66: 153–194.; EASL Clinical Practice Guidelines: Liver transplantation. Journal of Hepatology. 2016; 64 (2): 433–485.; Pawlotsky, Jean-Michel et al. EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology. 2018.; Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008; 14: 58–66.; Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383.; Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am. J. Transplant. 2006; 6 (7): 1586–1599.; Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol. 2008; 49: 274– 287. DOI:10.1016/j.jhep.2008.05.002.; Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso A, Delvart V et al. Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008; 14: 1766–1777. DOI:10.1002/lt.21635.; Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002: 237–244.; Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013; 19: 837–849.; Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med 2011; 364: 2405–2416.; Zeuzem S, Andreone P, Pol S et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364 (25): 2417–2428. DOI:10.1056/NEJMoa1013086.; Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010; 376: 705–716.; Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195–1206.; Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207–17.; Hulskotte E, Gupta S, Xuan F, van Zutven M, O‘Mara E, Feng H et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012; 56: 1622–1630.; Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54: 20–27.; Pungpapong S, Aqel BA, Koning L et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013; 19 (7): 690–700.; Coilly A, Dumortier J, Botta-Fridlund D et al. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future? Yu M-L, ed. PLoS ONE. 2015; 10 (9): e0138091. DOI:10.1371/journal.pone.0138091.; Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW et al. Protease inhibitor- based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann. Hepatol. 2014; 13: 525–532.; Burton JR Jr, O’Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease- inhibitor triple therapy. J. Hepatol. 2014; 61: 508–514. DOI:10.1016/j.jhep.2014.04.037 [PMC free article] [PubMed].; Werner CR, Egetemeyr DP, Nadalin S, Konigsrainer A, Malek NP, Lauer UM et al. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z. Gastroenterol. 2014; 52: 27–34. DOI:10.1055/s-0033-1356345.; Jacobson IM et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo- controlled trial. The Lancet. 2014; 384 (9941): 403–413.; Forns X, Lawitz E, Zeuzem S et al. Simeprevir (TMC435) with peginterferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub- populations in the PROMISE Phase III trial [abstract]. Hepatology. 2013; 58 (1): 737.; Ueda Y, Ikegami T, Soyama et al. Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience. Hepatol. Res. 2016; 46: 1285–1293. DOI:10.1111/hepr.12684.; Shinoda M et al. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatology Research. 2016; 46 (11): 1118–1128.; Charlton M et al. Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology. 2015; 148 (1): 108–117.; Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015; 61 (6): 1880–1886.; Brown RS, O’Leary JG, Reddy KR et al. Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2016; 22 (1): 24–33. DOI:10.1002/lt.24366.; Gutierrez JA, Carrion AF, Avalos D, O’Brien C, Martin P, Bhamidimarri KR et al. Sofosbuvir and Simeprevir for Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients. Liver Transpl. 2015.; Pyrsopoulos N et al. The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. European Journal of Gastroenterology & Hepatology. 2018; 30 (7): 761–765, DOI:10.1097/MEG.0000000000001101 [abstract].; Leroy VP, Georges-Philippe et al. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clinical Gastroenterology and Hepatology. 2015; 13 (11): 1993–2001.; Poordad F, Schiff ER, Vierling JM et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63 (5): 1493–1505. DOI:10.1002/hep.28446.; Aragwal K et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. Journal of Hepatology. 2017; 6: 34 [abstract].; Anty R, Favre AG, Coilly E, Rossignol P, Houssel-Debry C, Duvoux V et al. Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study. Hepatol. 2018. pii: S0168- 8278(18)32124-X. DOI:10.1016/j.jhep.2018.05.039. [Epub ahead of print] https://doi.org/10.1111/apt.14639.; Tronina O, Durlik M, Wawrzynowicz-Syczewska M, Buivydiene A, Katzarov K, Kupcinskas L et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+ Dasabuvir ± Ribavirin (OBV/PTV/r/ + DSV ±RBV). Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBERCEE Study. Ann. Transplant. 2017; 22: 199–207. DOI:10.12659/AOT.903535.; Ming-Lung Yu, Yao-Li Chen, Chung-Feng Huang, Kuo-Hua Lin, Ming-Lun Yeh, Ching-I. Huang. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real- world experience. Journal of the Formosan Medical Association. 2018; 117: 518–526.; Miuma S, Miyaaki H, Soyama A, Hidaka M, Takatsuki M, Shibata H et al. Utilization and efficacy of elbasvir/ grazoprevir for treating hepatitis C virus infection after liver transplantation. Hepatol. Res. 2018. DOI:10.1111/hepr.13204.; Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P et al. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018. DOI:10.1002/hep.30046.; https://journal.transpl.ru/vtio/article/view/919
-
9Academic Journal
Authors: K. V. Zhdanov, K. V. Kozlov, V. S. Sukachev, S. M. Zaharenko, S. S. Karyakin, A. V. Saulevich, D. Yu. Lobzin, M. V. Yaryemenko, K. S. Ivanov, Yu. I. Lyashenko, V. E. Karev, Yu. F. Zaharkiv, Yu. I. Bulan’kov, К. В. Жданов, К. В. Козлов, В. С. Сукачев, С. М. Захаренко, С. С. Карякин, А. В. Саулевич, Д. Ю. Лобзин, М. В. Яременко, К. С. Иванов, Ю. И. Ляшенко, В. Е. Карев, Ю. Ф. Захаркив, Ю. И. Буланьков
Source: Journal Infectology; Том 10, № 4 (2018); 6-13 ; Журнал инфектологии; Том 10, № 4 (2018); 6-13 ; 2072-6732 ; 10.22625/2072-6732-2018-10-4
Subject Terms: прогрессирование фиброза, sustained virological response, comorbid factors, progression of fibrosis, устойчивый вирусологический ответ, коморбидные факторы
File Description: application/pdf
Relation: https://journal.niidi.ru/jofin/article/view/797/657; Stanaway J.D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet. 2016 Sep; 388 (10049): 1081–1088.; Жданов, К.В. Реальная клиническая практика и ближайшие перспективы безинтерфероновой терапии пациентов с хроническим гепатитом С (генотип 1) / К.В. Жданов [и др.] // Инфекционные болезни. –2018. – № 16(2). – С. 98–103.; Dyson J., et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014 Jan; 60 (1):110-117; Satapathy S.K., Sanyal A.J. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin. Liver Dis. 2015; 35: 221–35.; Ивашкин, В.Т. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2 / В.Т. Ивашкин [и др.] // Рос. журнал гастроэнтерологии, гепатологии, колопроктологии. – 2015. – Т. 24, № 6. – С. 31–41.; Adinolfi L.E., Rinaldi L., Guerrera B. et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. International Journal of Molecular Sciences. – 2016; 6 (17): 803.; Жданов, К.В. Хронический гепатит С и неалкогольная жировая болезнь печени. Основные аспекты патогенеза / К.В. Жданов [и др.] // Вестник Российской военномедицинской академии. – 2018. – № 1(61). – С. 216–221.; Dulai P.S., Singh S., Patel J., Soni M., Prokop L.J., Younossi Z., et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65: 1557-1565.; Caligiuri A., Gentilini A., Marra F. Molecular pathogenesis of NASH. International Journal of Molecular Sciences. 2016; 17 (9):1575.; Crum-Cianflone N., Dilay A., Collins G., et al. Nonalcoholic Fatty Liver Disease (NAFLD) among HIV-Infected Persons. J. Acquir. Immune Defic. Syndr. 2009; 50(5): 464–73.; Puoti M, Moioli MC, Travi G, Rosootti R. The burden of liver disease in HIV-infected patients. Semin Liver Dis. 2012; 32:103-13.; Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and HCV: 2007 updated recommendations from the HCV-HIV Inter- national Panel. AIDS 2007; 21:1073-89.; Van Der Helm J, et al. Effect of HCV Infection on CauseSpecific Mortality After HIV Seroconversion, Before and After 1997. Gastroenterology, 2013; 144:751–760.; Asselah T., Rubbia-Brandt L., Marcellin P., Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006; 55: 123-130.; Price J.C. Liver Disease in the HIV-Infected Individual. Clin. Gastroenterol. Hepatol. 2010; 8(12): 1002 – 1012.; Жданов, К.В. Гепатит С и неалкогольная жировая болезнь печени у пациентов с ВИЧ-инфекцией / К.В. Жданов, К.В. Козлов, В.С. Сукачев // ВИЧ-инфекция и иммуносупрессии. – 2017. – № 1 (9). – С. 36–42.; Guaraldi G. et. al. Nonalcoholic Fatty Liver Disease in HIVInfected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. HIV/AIDS. 2008; 47: 250 – 257.; Pinzani M. Fatty Liver Disease: co-factor of HCV and evolving disease entity [Internet]. Available from: http://congress-ph.ru/common/htdocs/upload/fm/gepatology/2016/prez/2-1-1.pdf.; Сукачев, В.С. Оценка морфофункционального состояния тонкой кишки у больных хроническим гепатитом С : автореф. дис. . канд. мед. наук / В.С. Сукачев. – СПб., 2012.; Жданов, К.В. Дисбиоз кишечника при циррозе печени / К.В. Жданов, Д.А. Гусев, С.М. Захаренко, М.В. Куртуков, В.С. Сукачев // Журнал экспериментальной и клинической гастроэнтерологии. – 2011. – № 6. – С. 38–44.; Жданов, К.В. Синдром избыточного бактериального роста у больных хроническим гепатитом С / К.В. Жданов [и др.] // Журнал инфектологии. – 2011. – Т. 3, № 4. – С. 98–101.; Trivedi P. J., Adams D.H. Gut-liver immunity. J Hepatol 2016; 64: 1187-89.; Schneider K.M., Albers St., Trautwein Ch. Role of bile acids in the gut-liver axis. J Hepatol. 2018; 68:1083–1085.; Brandl K., Hartmann P., Jih L.J. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J. Hepatol. 2018 Aug; 69(2): 396–405; R. Schwabe, EASL 2018 (oral presentation). https:// ilc-congress.eu/wp-content/uploads/2018/04/EASL_ILCscientific-programme-2018.pdf; Зубкин, М.Л. Хроническая HCV-инфекция и патология почек / М.Л Зубкин [и др.] // Инфекционные болезни – 2017. – Т.15, № 4 – С. 68–76.; Negro F., Forton D., Craxi A., Sulkowski M.S., Feld J.J., Manns M.P. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015 Nov; 149(6): 1345-60.; Dammaco F., Racanelli V., Russi S., Sansonno D. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review // Clin Exp Med. 2016 Aug; 16(3): 233-42.; Dore G.J., Altice F., Litwin A.H., et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016; 165: 625-634.; Grebely J., Mauss S., Brown A., et al. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Clin Infect Dis. 2016; 63:1405-1411.; Grebely J., Dore G.J., Zeuzem S. et al. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clin Infect Dis. 2016;63:1479- 1481.; Grebely J, et al. EASL 2017. Abstract FRI-235.; https://www.hcvguidelines.org; EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol (2016).; Konerman M.A., Jones J.C., Harrison S.A. Pharmacotherapy for NASH: Current and emerging. J Hepatol. 2018; 68: 362-75.; https://journal.niidi.ru/jofin/article/view/797
-
10Academic Journal
Authors: O V Azovtzeva, S A Buzunova, G S Arkhipov, E I Arkhipova, T S Trofimova
Source: RUDN Journal of Medicine, Vol 0, Iss 1, Pp 18-24 (2014)
Subject Terms: вирусный гепатит С, ВИЧ-инфекция, генотип, противовирусные препараты, устойчивый вирусологический ответ, Medicine
File Description: electronic resource
-
11Academic Journal
Authors: Patlusov, Е. Р., Kovaleva, N. B., Pukhtinskaya, P. S., Патлусов, Е. П., Ковалева, Н. Б., Пухтинская, П. С.
Subject Terms: HEPATITIS C, LIVER FIBROSIS, SUSTAINED VIROLOGICAL RESPONSE, PEGYLATED INTERFERON, CEPEGINTERFERON ALFA, ХРОНИЧЕСКИЙ ГЕПАТИТ С, ФИБРОЗ ПЕЧЕНИ, УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ, ПЕГИЛИРОВАННЫЙ ИНТЕРФЕРОН, ЦЕПЭГИНТЕРФЕРОН АЛЬФА
File Description: application/pdf
Relation: Уральский медицинский журнал. 2016. T. 144, № 11.; http://elib.usma.ru/handle/usma/13373
Availability: http://elib.usma.ru/handle/usma/13373
-
12Academic Journal
Authors: Bogomolov P.O., Matsievich M.V., Kokina K.Y., Kuz'mina O.S., Koblov S.V., Voronkova N.V., Petrachenkova M.Y., Bueverov A.O., Uvarova O.V., Fedosova E.V., Trofimova M.N., Beznosenko V.D., Kudryavtseva E.N., Kondratenko E.M., Gorbunova L.S., Shilkina I.M., Sheshukova T.N., Kovalev I.N., Sadovskaya G.V., Kosheleva N.V., Gumerova Y.Y., Azarova I.N., Ivannikova S.V., Cherenkova E.N., Gorshilina N.A., Samsonyan M.L., Sinitsyna V.A., Kiyan S.I., Kudrya O.A., Chernyavskaya G.G.
Source: Almanac of Clinical Medicine; No 40 (2015); 48-57 ; Альманах клинической медицины; No 40 (2015); 48-57 ; 2587-9294 ; 2072-0505 ; 10.18786/2072-0505-2015-40
Subject Terms: chronic hepatitis C, short course of antiviral therapy, telaprevir, IL28B, sustained virological response, хронический гепатит С, короткий курс противовирусной терапии, телапревир, интерлейкин 28B, устойчивый вирусологический ответ
File Description: application/pdf
-
13Academic Journal
Authors: АНАСТАСИЙ И.А.
File Description: text/html
-
14Academic Journal
Authors: Азовцева, Ольга, Бузунова, Светлана, Архипов, Георгий, Архипова, Екатерина, Трофимова, Татьяна
Subject Terms: ВИРУСНЫЙ ГЕПАТИТ С, ВИЧ-ИНФЕКЦИЯ, ГЕНОТИП, ПРОТИВОВИРУСНЫЕ ПРЕПАРАТЫ, УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ
File Description: text/html
-
15Academic Journal
Authors: Sharapova, L. P., Medvedeva, I. V., Chesnokov, E. V., Sokolov, S. A., Igoshina, О. K., Seleznev, D. O., Vorobyev, I. A., Шарапова, Л. П., Медведева, И. В., Чесноков, Е. В., Соколов, С. А., Игошина, О. В., Селезнев, Д. О., Воробьев, И. А.
Subject Terms: CHRONIC HEPATITIS C, OPISTHORCHIASIS, ANTIVIRAL THERAPY HCH, SUSTAINED VIROLOGIC RESPONSE, ХРОНИЧЕСКИЙ ГЕПАТИТ С, ОПИСТОРХОЗ, ПРОТИВОВИРУСНАЯ ТЕРАПИЯ ГЕПАТИТА С, УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ
File Description: application/pdf
Relation: Уральский медицинский журнал. 2013. T. 112, № 7.; http://elib.usma.ru/handle/usma/15033
Availability: http://elib.usma.ru/handle/usma/15033
-
16Academic Journal
Authors: Ягода, Александр, Корой, Павел, Гилязова, Гузель
Subject Terms: ХРОНИЧЕСКИЙ ВИРУСНЫЙ ГЕПАТИТ С, CHRONIC VIRAL HEPATITIS С, Е-СЕЛЕКТИН, Е-SELECTIN, L-СЕЛЕКТИН, Р-СЕЛЕКТИН, ПРОТИВОВИРУСНАЯ ТЕРАПИЯ, УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ
File Description: text/html
-
17Academic Journal
Authors: Притулина, Ю., Астапченко, Д., Саломахин, Г.
Subject Terms: ХРОНИЧЕСКИЙ ГЕПАТИТ С, ПРОТИВОВИРУСНАЯ ТЕРАПИЯ, ПОБОЧНЫЕ ЭФФЕКТЫ, УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ
File Description: text/html
-
18Academic Journal
Authors: Корой, Павел, Ягода, Александр, Мухорамова, Ирина
Subject Terms: ХРОНИЧЕСКИЙ ВИРУСНЫЙ ГЕПАТИТ С,МОЛЕКУЛЫ МЕЖКЛЕТОЧНОЙ АДГЕЗИИ,ПРОТИВОВИРУСНАЯ ТЕРАПИЯ,УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ
File Description: text/html
-
19Academic Journal
Source: Актуальная инфектология.
Subject Terms: ГЕПАТИТ С,HEPATITIS C,УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ,SUSTAINED VIROLOGICAL RESPONSE,GENOFIBROTEST,СТіЙКА ВіРУСОЛОГіЧНА ВіДПОВіДЬ,ГЕНОФіБРОТЕСТ,ГЕНОФИБРОТЕСТ, 3. Good health
File Description: text/html
-
20Academic Journal
Source: Вестник Российского университета дружбы народов. Серия: Медицина.
Subject Terms: ВИРУСНЫЙ ГЕПАТИТ С, ВИЧ-ИНФЕКЦИЯ, ГЕНОТИП, ПРОТИВОВИРУСНЫЕ ПРЕПАРАТЫ, УСТОЙЧИВЫЙ ВИРУСОЛОГИЧЕСКИЙ ОТВЕТ, 3. Good health
File Description: text/html
